 | |
- close
- close
|
|
Topic
Top news source/blog that we're missing
Why do you recommend this news source?
|
||
WIKI ANALYSIS
Medtronic (NYSE:MDT) is the world's largest medical device company. MDT is best known for its pacemakers but also produces a wide range of other medical devices, including external defibrillators, insulin pumps and image guided surgery systems. In fiscal 2007 Medtronic posted revenues of $12.3B.
In 2007, Medtronic issued a recall of its Sprint Fidelis leads. These wires, which connect the pacemakers to the hearts of patients, were found to sometimes malfunction and have already been implicated in several deaths. In addition to the expense associated with replacing the leads (embedded in the patients' chest), Medtronic may face substantial legal liability. On the other hand, the company could benefit substantially from the growing diabetes market. Diabetes is strongly related to obesity, and as obesity rates continue to rise throughout the world, the market for diabetes is expected grow accordingly.
Business Overview
MDT operates in eight main segments:
- Cardiac Rhythm Disease Management: MDT is the world’s leading supplier of pacemakers. This is the largest division of the company and accounted for 40% of 2007 revenue. [1]
- Spinal and Navigation: spinal products and image guided surgery systems that are used by surgeons during precision cranial and orthopedic surgeries. [2]
- Vascular: products and therapies such as stents which are to treat coronary artery disease, aneurysms, and peripheral vascular disease. [3]
- Neurological: devices for the treatment of neurological, urological, and gastrointestinal disorders. One of the main devices is a neurostimulation system, which is about the size of a stopwatch and can be implanted under the skin to deliver electrical pulses to the spinal cord. [4]
- Diabetes: devices such as external insulin pumps and glucose monitoring (CGM) systems for maintaining control of glucose levels and supporting the treatment of diabetes. [5]
- Cardiac Surgery: products used for procedures such as heart valve repair and replacement. These include perfusion systems, which oxygenate and circulate a patient’s blood during heart surgery, and products used for the repair and replacement of heart valves, etc.[6]
- ENT: has products and therapies to treat a broad range of diseases and conditions of the ear, nose and throat. These include tissue-removal devices, surgical instruments, image-guided surgery systems, and others. [7]
- Physio-Control: products such as external defibrillators which are used on victims of cardiac arrest. [8]
In 2007, MDT had revenue of $12,299 million. This was a 9% increase over the $11,292 million generated in 2006. CRDM, the largest segment, only grew 2 percent to $4.876 billion. Instead, the growth was led by Vascular sales which increased 28% to $1.205 billion, Diabetes sales which increased 20% to $863 million, and Neurological sales increased 16% $1.183 billion. [10]
US sales accounted for 64% of revenue, with international revenues accounting for the remaining 36%.
Key Trends and Forces
Medicare coverage patterns
Health coverage is an important determining factor when patients and doctors choose among various treatment options. Medicare coverage is particularly significant in that it directly affects over forty million Americans, how much patients have to pay for Medtronic products, and how much Medtronic will receive in payments from Medicare. Currently, Medicare and other third party payors are emphasizing more cost-effective medical devices, by limiting the reimbursement they will cover. Furthermore, even if a new medical device is cleared by the FDA, Medtronic faces limited demand for the device until Medicare and other payors approve the device for reimbursement. For example, in 2005 MDT conducted a large study on Sudden Cardiac Death in Heart Failure and showed the effectiveness of its ICD. Following this study, Medicare expanded coverage of ICDs for heart patients, which boosted MDT's revenues.
Government Regulation
Medtronic and its competitors are all heavily affected by government regulation, especially by the FDA, which is responsible for regulating food, dietary supplements, drugs, medical devices, and other products in the United States. Without FDA approval, Medtronic cannot sell any of its medical devices to the public. If any of Medtronic's devices fail FDA approval, it can adversely affect the company's sales.
Diabetes
Diabetes currently affects around 200 million people worldwide, including 21 million people in the U.S. It is estimated that more than $132 billion is spent annually on diabetes and its complications. One of the key risk factors for diabetes is Obesity, which has been on the rise in the United States. MDT currently has several products that serve the diabetic market, and it represents an opportunity for MDT to generate additional revenue in this large and expanding market. In 2007, MDT's diabetes division had revenue of $863 million and experienced growth of 20% over 2006.
Saturation of Implantable Cardiac Rhythm Devices (ICD) Market
ICDs are stopwatch-sized devices that monitor the heart and deliver appropriate therapy when an abnormal heart rhythm is detected. Medtronic holds over 50% market share for ICDs and this product contribute about 25% of Medtronic's sales. ICDs usage has grown substantially over the years, due to trial results which showed ICDs reduced death by 23% in people with moderate heart failure compared to those who did not receive ICDs. [13] However, growth in this market has been declining recently as the patient population which ICDs serve is substantially penetrated. If MDT can't sell as many ICDs as it has in the past, its sales may be adversely affected.
Market Share
Medtronic dominates the diabetes, Pacing and ICD market with 65%, 53% and 52% market share respectively.
Competition
As mentioned above, MDT faces strong competition in nearly every segment that it operates in. Some of its chief competitors overall include Boston Scientific (BSX), Stryker (SYK), Zimmer Holdings (ZMH), St. Jude Medical (STJ) and JOHNSON & JOHNSON (JNJ).
| Company | Total Sales | Net Income |
|---|---|---|
| Medtronic | $12,299 M [14] | $2,802 M [15] |
| Zimmer Holdings (ZMH) | $3,496 M [16] | $835 M [17] |
| Stryker (SYK) | $5,406 M [18] | $778 M [19] |
| Boston Scientific (BSX) | $7,821 M [20] | ($3,577) M [21] |
| JOHNSON & JOHNSON (JNJ) | $53,194 M [22] | $11,053 M [23] |
Primary competitors in their various business lines include:
- Spinal and Navigation: Zimmer Holdings (ZMH), JOHNSON & JOHNSON (JNJ), Stryker (SYK), Synthes-Stratec, Inc., and Kyphon (KYPH). [25]
- Vascular: Boston Scientific (BSX), JOHNSON & JOHNSON (JNJ), and Abbott Laboratories (ABT).[26]
- Neurological: Boston Scientific (BSX) and St. Jude Medical (STJ). [27]
- Diabetes: JOHNSON & JOHNSON (JNJ), Abbott Laboratories (ABT), and Roche Pharmaceuticals (RHHBY). [28]
- Cardiac Surgery: Edwards Lifesciences (EW), Boston Scientific (BSX), JOHNSON & JOHNSON (JNJ), and St. Jude Medical (STJ)[29]
- Physio-Control: Cardiac Science (CSCX), Zoll Medical (ZOLL), and Royal Philips Electronics. [31]
References
- ↑ MDT 2007 10k, Pg 2
- ↑ MDT 2007 10k, Pg 5
- ↑ MDT 2007 10k, Pg 9
- ↑ MDT 2007 10k, Pg 13
- ↑ MDT 2007 10k, Pg 15
- ↑ MDT 2007 10k, Pg 16
- ↑ MDT 2007 10k, Pg 18
- ↑ MDT 2007 10k, Pg 20
- ↑ MDT 2007 10k, Exhibit 13, Page 7
- ↑ MDT 2007 10k, Exhibit 13, Page 3
- ↑ MDT 2007 10k, Exhibit 13, Page 38
- ↑ MDT 2007 10k, Pg 24
- ↑ MDT 2007 10k, Pg 4
- ↑ MDT 2007 10k, Exhibit 13
- ↑ MDT 2007 10k, Exhibit 13
- ↑ ZMH 2006 10k
- ↑ ZMH 2006 10k
- ↑ SYK 2006 10k, Pg. 42
- ↑ SYK 2006 10k, Pg. 42
- ↑ BSX 2006 10k
- ↑ BSX 2006 10k
- ↑ JNJ 2006 10k
- ↑ JNJ 2006 10k
- ↑ MDT 2007 10k, Pg 2
- ↑ MDT 2007 10k, Pg 5
- ↑ MDT 2007 10k, Pg 9
- ↑ MDT 2007 10k, Pg 13
- ↑ MDT 2007 10k, Pg 15
- ↑ MDT 2007 10k, Pg 16
- ↑ MDT 2007 10k, Pg 18
- ↑ MDT 2007 10k, Pg 20
| ||||||
|
|
